Page last updated: 2024-10-25

deferoxamine and Leukemia, Myelomonocytic, Chronic

deferoxamine has been researched along with Leukemia, Myelomonocytic, Chronic in 1 studies

Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.

Leukemia, Myelomonocytic, Chronic: A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Schmidt, D1
Finke, J1

Other Studies

1 other study available for deferoxamine and Leukemia, Myelomonocytic, Chronic

ArticleYear
[Bull's-Eye Maculopathy with Deferoxamine Treatment].
    Klinische Monatsblatter fur Augenheilkunde, 2004, Volume: 221, Issue:3

    Topics: Aged; Anemia; Deferoxamine; Electroretinography; Erythrocyte Transfusion; Ferritins; Fluorescein Ang

2004